Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | recruiting | Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05730816 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI(MAGIC-AKI) | recruiting | Phase 2 | 130 | Brigham and Women's HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | recruiting | N/A | 397 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06538376 | Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | recruiting | N/A | 230 | Brigham and Women's HospitalOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT(IMPALA) | recruiting | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | recruiting | Phase 1 / Phase 2 | 52 | Baylor College of MedicineOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05538806 | TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study(TIGER Meso) | recruiting | — | 198 | NovoCure Ltd.INDUSTRY | 3 | Aug 22, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06790082 | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma(FAPI-PM) | recruiting | Phase 2 | 70 | Aalborg University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | recruiting | Phase 2 | 56 | University of ChicagoOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06946498 | First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.(FLAT) | recruiting | N/A | 100 | National and Kapodistrian University of AthensOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06910449 | Hemithoracic Arc Radiotherapy Post Pleural Decortication | recruiting | N/A | 45 | Cairo UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06886672 | Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS(MAGNETS) | recruiting | — | 60 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04996017 | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)(AtezoMeso) | recruiting | Phase 3 | 162 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06726564 | A Study of MT027 in Patients with Pleural Malignant Tumors | recruiting | Phase 1 | 18 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06637345 | Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)(MESORTIBO) | recruiting | — | 52 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06536179 | New Preclinical and Clinical Approaches to Mesothelioma | recruiting | — | 70 | Marco Emilio BianchiOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02073500 | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies(PSM) | recruiting | — | 300 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials